Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial

Conclusions
The maintenance of IMs, with or without low-dose GC, was found to be superior to withdraw GC+IM in preventing relapse for long-time stable IgG4-RD.

Trial registration number
NCT04124861.

Source: Annals of the Rheumatic Diseases - April 11, 2024 Category: Rheumatology Authors: Peng, L., Nie, Y., Zhou, J., Wu, L., Chen, X., Wang, F., Li, J., Peng, Y., Lu, H., Zhao, L., Li, M., Zhao, Y., Zeng, X., Fei, Y., Zhang, W. Tags: ARD, IgG4 related disease Source Type: research